Cancer mortality in Europe, 1990-1994, and an overview of trends from 1955 to 1994

European Journal of Cancer

Volumn 35, Issue 10, 1999, Pages 1477-1516

  Levi, F ^a,b   Lucchini, F ^a,b   Negri, E ^a   Boyle, P ^a,b   La Vecchia, C ^a,b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Epidemiology; Europe; Mortality; Neoplasms; Time trends

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; BULGARIA; CANCER; CANCER MORTALITY; COLORECTAL CANCER; CONTROLLED STUDY; CZECH REPUBLIC; DENMARK; EUROPE; FEMALE; FRANCE; GERMANY; GREECE; HUMAN; HUNGARY; LUNG CANCER; MALE; MORTALITY; PORTUGAL; PRIORITY JOURNAL; SWEDEN; UNITED KINGDOM; UTERUS CANCER;

ADULT; AGE DISTRIBUTION; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; MORTALITY; NEOPLASMS; PROGNOSIS; TIME FACTORS;

EID: 0032832193     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00154-9     Document Type: Article

References (84)

1. La Vecchia G, Lucchini F, Negri E, Boyle P, Maisonneuve P, Levi F. Trends of cancer mortality in Europe, 1955-1989: I, Digestive sites; II, Respiratory tract, bone, connective and soft tissue sarcomas, and skin; III, Breast and genital sites; IV, Urinary tract, eye, brain and nerves, and thyroid; V, Lymphohaemopoietic and all cancers. Eur J Cancer 1992, 28A, 132-235, 514-599, 927-998, 1210-1281, 1509-1581.
2. Doll R. Health and the environment in the 1990s. Am J Publ Health 1992, 82, 933-941.
3. Negri E, La Vecchia G, Franceschi S, Levi F. Patterns of mortality from major cancers in Europe. Cancer Epidemiol Biomarkers Prev 1994,3, 531-536.
4. Hadju P, McKee M, Bojan F. Changes in premature mortality differentials by marital status in Hungary and in England and Wales. Eur J Publ Health 1995, 5, 259-264.
5. Zatonski WA, Boyle P. Health transformations in Poland after 1988. J Epidemiol Biostat 1996, 1, 183-187.
6. Boyle P. Global burden of cancer. Lancet 1997, 349(Suppl. 2), SII23-26.
7. Evstifeeva T, MacFarlane G, Robertson C. Trends in cancer mortality in central European countries. EurJ Publ Health 1997, 7, 169-176.
8. La Vecchia G, Levi F, Lucchini F, Negri E. Trends in mortality from major diseases in Europe, 1980-1993. Eur J Epidemiol 1998, 14, 1-8.
9. Levi F, Lucchini F, Boyle P, Negri E, La Vecchia G. Cancer incidence and mortality in Europe, 1989-92. J Epidemiol Biostat 1998,3,295-373.
10. Leon DA, Chenet L, Shkolnikov VM, et al. Huge variation in Russian mortality rates 1984-94: artefact, alcohol, or what? Lancet 1997,350, 383-388.
11. La Vecchia C, Negri E, Levi F, Decarli A, Boyle P. Cancer mortality in Europe: effects of age, cohort of birth and period of death. Eur J Cancer 1998, 34, 118-141.
12. Cole P, Rodu B. Declining cancer mortality in the United States. Cancer 1996, 76, 2045-2048.
13. World Health Organization. International Classification of Disease, 8th Revision. Geneva, World Health Organization, 1967.
14. World Health Organization. International Classification of Disease, 9th Revision. Geneva, World Health Organization, 1977.
15. Doll R, Smith PG. Comparison between registries: age-standardized rates. In Waterhouse JAH, Muir CS, Shanmugaratnam K, et al, eds. Cancer Incidence in Five Continents, Vol. IV. IARC Scient Publ No 42. Lyon, International Agency for Research on Cancer, 1982,671-675.
16. Percy C, Staneck E, Gloeckler L. Accuracy of cancer death certification and its effects on mortality statistics. Am J Publ Health 1981,71,242-250.
17. Boyle P. Relative value of incidence and mortality data in cancer research. Recent Results Cancer Res 1989, 114, 41-63.
18. Levi F, La Vecchia C, Lucchini F, Te VC, Franceschi S. Mortality from Hodgkin's disease and other lymphomas in Europe, 1960-1990. Oncology 1995, 52, 93-96.
19. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risk of cancer in the United States today. J Natl Cancer Inst 1981,66, 1191-1308.
20. La Vecchia G, Tavani A, Franceschi S, Levi F, Corrao G, Negri E. Epidemiology and prevention of oral cancer. Oral Oncol 1997, 33, 302-313.
21. Moller H, Boyle P, Maisonneuve P, La Vecchia C, Jensen OM. Changing mortality from esophageal cancer in males in Denmark and other European countries in relation to changing level of alcohol consumption. CancerCauses Control 1990, 1, 181-188.
22. Franceschi S, Levi F, La Vecchia C. Epidemiology of gastric cancer in Europe. Eur J Cancer Prev 1994, 352, 5-10.
23. Zatonski W, La Vecchia C, Levi F, Negri E, Lucchini F. Descriptive epidemiology of gall-bladder cancer in Europe. J Cancer Res Clin Oncol 1993, 119, 165-171.
24. Fernandez E, La Vecchia G, Porta M, Negri E, Lucchini F, Levi F. Trends in pancreatic cancer mortality in Europe, 1955-89. IntJ Cancer 1994, 57, 786-791.
25. Boyle P. Tobacco and cancer, the European perspective. Ann Oncol 1995, 6, 435-437.
26. La Vecchia C, Boyle P, Franceschi S, et al. Smoking and cancer with emphasis on Europe. Eur J Cancer 1991, 27A, 94-104.
27. Peto R, Lopez A, Boreham J, Thun M, Heath Jr C. Mortality from smoking in developed countries 1950-2000. Indirect estimates from National Vital Statistics. New York, Oxford University Press, 1994, 658pp.
28. Wynder EL. The past, present, and future of the prevention of lung cancer. Cancer Epidemiol Biomarkers Prev 1998, 7, 735-748.
29. Price B. Analyses of current trends in US mesothelioma incidence. Am J Epidemiol 1997, 145, 211-218.
30. Peto J, Decarli A, La Vecchia G, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999, 79, 666-672.
31. Zahm SA, Tucker MA, Fraumeni JF Jr. Soft tissue sarcomas. In Schottenfeld D, Fraumeni JF Jr, eds. Cancer Epidemiology and Prevention. New York, Oxford University Press, 1996, 985-999.
32. La Vecchia C, Lucchini F, Negri E, Levi F. Recent declines in worldwide mortality from cutaneous melanoma in young and middle age. Int J Cancer 1999, 81, 62-66.
33. La Vecchia C. Diet in the aetiology of cancer: a review. Eur J Cancer 1994, 30A, 224-225.
34. Peto R. Mortality from breast cancer in UK has decreased suddenly. Brit Med J 1998, 317, 476-477.
35. Pecorelli S, Creasman WT, Petterson F. FIGO Annual Report on the Results of Treatment in Gynaecological Cancer. Twenty-third Volume. J Epidemiol Biostat 1998,3, 1-168.
36. La Vecchia C, Levi F, Franceschi S. Screening of cancer, 1995: an update. Ann Oncol 1995, 6, 537-541.
37. Parazzini F, Franceschi S, La Vecchia C, Fasoli M. The epidemiology of ovarian cancer. Gynecol Oncol 1991, 43, 9-23.
38. Jacobsen SJ, Katusic SK, Bergstrahl EJ, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. J Am Med Assoc 1995, 274, 1445-1449.
39. Boyle P. Prostate cancer: creation and control of an epidemic. J Epidemiol Biostat 1996, 1, 65-67.
40. Boyle P, Maisonneuve P, Kaye SB. Testicular cancer in Central Europe. Lancet 1990, 335, 1033.
41. Becker N, Boyle P. Decline in mortality from testicular cancer in West Germany after reunification. Lancet 1997, 350, 744.
42. La Vecchia C, Levi F, Lucchini F, Garattini S. Progress of anticancer drugs in reducing mortality from selected cancers in Europe: an assessment. Anti-Cancer Drugs 1991, 2, 215-221.
43. Boyle P, Maisonneuve P, Napalkov P. Urological cancers: an epidemiological overview of a neglected problem. J Epidemiol Biostat 1997,2, 125-145.
44. Tavani A, La Vecchia C. Epidemiology of renal carcinoma. J Nephrol 1997, 70, 93-106.
45. Franceschi S, Boyle P, Maisonneuve P, et al. The epidemiology of thyroid cancer. Grit Rev Oncol 1993, 4, 25-52.
46. Franceschi S, La Vecchia C. Thyroid cancer. Cancer Surv 1994, 19, 393-421.
47. Turesson I, Zettervall O, Cuzick J, Waldenström JG, Velez R. Comparison of trends in the incidence of multiple myeloma in Malmö, Sweden, and other countries, 1950-1979. N Engl J Med 1984,310,421-424.
48. Vartiainen E, Puska P, Jousilahti P, Korhonen HJ, Tuomilehto J, Nissinen A. Twenty-year trends in coronary risk factors in North Karelia and other areas in Finland. Int J Epidemiol 1994, 23, 495-504.
49. Dunnick JK, Hailey JR. Toxicity and carcinogenicity studies of quercetin, a natural component of foods. Fund Appl Toxicol 1992, 19,423-431.
50. Fiala ES, Reddy BS, Weisburger JH. Naturally occurring anticarcinogenic substances in foodstuffs. Ann Rev Nutrit 1985, 5, 295-321.
51. Hollman PC, Van Trijp JM, Buysman MN, et al. Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man. FEES Lett 1997, 418, 152-156.
52. Pratt CB, Relling MV, Meyer WH, Douglass EC, Kellie SJ, Avery L, Phase I. study of flavone acetic acid (NSC 347512, LM975) in patients with pediatrie malignant solid tumors. Am J Clin Oncol 1991, 14, 483-486.
53. Huang YT, Kuo ML, Liu JY, Huang SY, Lin JK. Inhibitions of protein kinase c and proto-oncogene expressions in NIH 3T3 cells by apigenin. Eur J Cancer 1996, 32A, 146-151.
54. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972, 26, 239-257.
55. McGowan AJ, Fernandes RS, Verhaegen S, Cotter TG. Zinc inhibits UV radiation-induced apoptosis but fails to prevent subsequent cell death. Int J Radiat Biol 1994, 66, 343-349.
56. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumour cells - a mechanism of immune evasion? Nature Med 1996, 2, 1361-1366.
57. Enari M, Hase A, Nagata S. Apoptosis by a cytosolic extract from Fas-activated cells. EMBO J 1995, 14, 5201-5208.
58. Dive G, Hickman JA. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 1991,64, 192-196.
59. Gunji H, Kharbanda S, Kufe D. Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1 -beta-D-arabinofuranosylcytosine. Cancer Res 1991, 51, 741-743.
60. Cotter TG, Glynn JM, Echeverri F, Green DR. The induction of apoptosis by chemotherapeutic agents occurs in all phases of the cell cycle. Anticancer Res 1992, 12, 773-779.
61. Martin SJ, Green DR. Protease activation during apoptosis: death by a thousand cuts? Cell 1995, 82, 349-352.
62. Nagata S. Apoptosis by death factor. Cell 1997, 88, 355-365.
63. Takahashi A, Alnemri ES, Lazebnik YA, et al. Cleavage of lamin A by Mch2 alpha but not CPP32: multiple interleukin 1 beta-converting enzyme-related proteases with distinct substrate recognition properties are active in apoptosis. Proc Natl Acad Sci USA 1996,93, 8395-8400.
64. Faucheu C, Diu A, Chan AW, et al. A novel human protease similar to the interleukin-1 beta converting enzyme induces apoptosis in transfected cells. EMBO J 1995, 14, 1914-1922.
65. Tewari M, Quan LT, O'Rourke K, et al. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995,81, 801-809.
66. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2 : release of cytochrome c from mitochondria blocked. Science 1997,275, 1129-1132.
67. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for bcl-2 regulation of apoptosis. Science 1997, 275, 1132-1136.
68. Hofmann K, Bucher P, Tschopp J, The CARD, domain: a new apoptotic signaling motif. Trends Biochem Sci 1997, 22, 155-156.
69. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-l/Caspase-9 complex initiates an apoptotic protease cascade. Cell 1997, 91, 479-489.
70. Lin YL, Juan IM, Chen YL, Liang YC, Lin JK. Composition of polyphenols in fresh tea leaves and associations of their oxygen-radical-absorbing capacity with antiproliferative actions in fibroblast cells. J Agric Food Chem 1996,44, 1387-1394.
71. Csokay B, Prajda N, Weber G, Olah E. Molecular mechanisms in the antiproliferative action of quercetin. Life Sci 1997, 60, 2157-2163.
72. Lepley DM, Felling JC. Induction of p21/WAFl and Gl cell-cycle arrest by the chemopreventive agent apigenin. Molec Carcinogen 1997, 19, 74-82.
73. Kang TB, Liang NC. Studies on the inhibitory effects of quercetin on the growth of HL-60 leukemia cells. Biochem Pharmacol 1997,54, 1013-1018.
74. Wei YQ, Zhao X, Kariya Y, Fukata H, Teshigawara K, Uchida A. Induction of apoptosis by quercetin: involvement of heat shock protein. Cancer Res 1994, 54, 4952-4957.
75. Plaumann B, Pritsche M, Rimpler H, Brandner G, Hess RD. Flavonoids activate wild-type p53. Oncogene 1996, 13, 1605-1614.
76. Reed JC. Cytochrome c: can't live with it - can't without it. Cell 1997,91, 559-562.
77. Middleton E Jr, Kandaswami C. The impact of plant flavonoids on mammalian biology: implications for immunity, inflammation and cancer. In Harborne TH, Liss AR, eds. Flavonoids: Advances in Research Since 1986. New York, Chapman and Hall 1994,619-625.
78. Ferriola PC, Cody V, Middleton E. Protein kinase C inhibition by plant flavonoids. Kinetic mechanisms and structure-activity relationships. Biochem Pharmacol 1989, 38, 1617-1624.
79. Geahlen RL, Koonchanok NM, McLaughlin JL, Pratt DE. Inhibition of protein-tyrosine kinase activity by flavanoids and related compounds. J Natl Products 1989, 52, 982-986.
80. Cushman M, Nagarathnam D, Burg DL, Geahlen RL. Synthesis and protein-tyrosine kinase inhibitory activities of flavonoid analogues. J Med Chem 1991, 34, 798-806.
81. Agullo G, Gamet-Payrastre L, Manenti S, Viala C, Remesy C, Chap H, Payrastre B. Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. Biochem Pharmacol 1997, 53, 1649-1657.
82. Jing Y, Waxman S. Structural requirements for differentiation-induction and growth-inhibition of mouse erythroleukemia cells by isoflavones. Anticancer Res 1995, 15, 1147-1152.
83. Shimoi K, Masuda S, Furugori M, Esaki S, Kinae N. Radioprotective effect of antioxidative flavonoids in gamma-ray irradiated mice. Carcinogenesis 1994, 15, 2669-2672.